Clinical Trials Browser

Recruiting × Carcinoma, Non-Small-Cell Lung × aflutinib × Clear all

NCT07185997 2026-02-10

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Phase 3 Recruiting

480 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms

NCT07304739 2025-12-26

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Phase 2 Recruiting

30 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06652048 2025-11-21

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Phase 2 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Phase NA Recruiting

60 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05379803 2024-09-19

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Phase 2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06394674 2024-07-26

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Phase 2 Recruiting

84 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06192849 2024-01-05

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Phase 2 Recruiting

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04401059 2023-12-27

SELECT-2

Phase 4 Recruiting

744 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05445310 2023-02-16

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Phase 2 Recruiting

114 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05334277 2022-08-31

FOCUS-C

Phase 2 Recruiting

280 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung